OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
NCT ID: NCT00040183
Last Updated: 2018-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
569 participants
INTERVENTIONAL
2001-11-29
2004-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
NCT00026338
Tarceva and Capecitabine for Pancreatic Cancer
NCT00125021
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
NCT00033241
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
NCT00063947
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
NCT00642733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarceva (erlotinib HCl, OSI-774)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Must have evidence of disease (clinical or radiological). Male or female, 18 years or older. Patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented.
All toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization.
Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Cancer Trials Group
NETWORK
OSI Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Clinical Research Center
Tucson, Arizona, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
Loma Linda University Cancer Institute
Loma Linda, California, United States
Metropolitan Hematology/Oncology Medical Group, Inc.
Los Angeles, California, United States
UCLA Medical Center
Los Angeles, California, United States
Kaiser Permanente
San Diego, California, United States
DeQuattro Community Cancer Center
Manchester, Connecticut, United States
New Britain General Hospital
New Britain, Connecticut, United States
Eastern Connecticut Oncology
Norwich, Connecticut, United States
Carl and Dorothy Bennett Cancer Center
Stamford, Connecticut, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Oncology Hematology Group of South Florida
Miami, Florida, United States
Ocala Oncology
Ocala, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Atlanta Cancer Center
Atlanta, Georgia, United States
Onc/Hem Associates of Central Illinois
Peoria, Illinois, United States
Hematology Oncology Associates of Illinois
Skokie, Illinois, United States
Carle Cancer Center
Urbana, Illinois, United States
University of Iowa Hospital & Clinics
Iowa City, Iowa, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
Norton Healthcare, Inc.
Louisville, Kentucky, United States
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
J Gurtler, Hematology and Oncology
Metairie, Louisiana, United States
Annapolis Medical Specialists
Annapolis, Maryland, United States
Sinai Hospital
Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
St Elizabeth Medical Center
Boston, Massachusetts, United States
New England Medical Center
Boston, Massachusetts, United States
Berkshire Hematology & Oncology, PC
Pittsfield, Massachusetts, United States
Baystate Medical Center
Springfield, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
New Hampshire Oncology-Hematology PA
Hooksett, New Hampshire, United States
St Barnabas Medical Center
Livingston, New Jersey, United States
Arena Oncology Associates
Great Neck, New York, United States
New York University School of Medicine
New York, New York, United States
St Luke's-Roosevelt Hospital
New York, New York, United States
Interlakes Oncology & Hematology, P.C.
Rochester, New York, United States
Stony Brook University Hospital
Stony Brook, New York, United States
Presbyterian Hospital
Charlotte, North Carolina, United States
Odyssey Research Services
Bismarck, North Dakota, United States
University Hospitals of Cleveland
Cleveland, Ohio, United States
Chiles Research Cancer Center
Portland, Oregon, United States
Hematology & Oncolgy Assoc of NE PA
Dunmore, Pennsylvania, United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Charleston Hematology/Oncology
Charleston, South Carolina, United States
Sarah Cannon Cancer Center
Nashville, Tennessee, United States
Arlington Cancer Centre
Arlington, Texas, United States
Southwest Regional Cancer Center
Austin, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Tyler Hematology Oncology PA
Tyler, Texas, United States
Green Mountain Oncology Group
Bennington, Vermont, United States
Hematology & Oncology Associates of Virginia, Ltd.
Richmond, Virginia, United States
Western Washington Oncology Inc.
Olympia, Washington, United States
Southwest Washington Medical Center
Vancouver, Washington, United States
Oncology of Wisconsin
Milwaukee, Wisconsin, United States
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Hospital Britanico
Buenos Aires, , Argentina
Instituto Oncologico Angel Roffo
Buenos Aires, , Argentina
Instituto Alexander Fleming
Buenos Aires, , Argentina
Hospital Churruca Visca
Buenos Aires, , Argentina
Centro Medico Confidence
Buenos Aires, , Argentina
Concord Hospital
Concord, New South Wales, Australia
Newcastle Mater Hospital
HRMC Waratah, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Ashford Cancer Centre
Ashford, South Australia, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Frankston Hospital
Frankston, Victoria, Australia
Austin & Repatriation Medical Centre
Heidelberg, Victoria, Australia
Institute Jules Bordet
Brussels, , Belgium
Nucleo de Oncolgia da Bahia
Salvador, Estado de Bahia, Brazil
Hospital Vera Cruz S/A
Barro Prêto, Minas Gerais, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
BC Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Pentincton Regional Hospital
Pentincton, British Columbia, Canada
Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
BCCA VAncouver Centre
Vancouver, British Columbia, Canada
BCCA- Vancouver Island Centre
Victoria, British Columbia, Canada
CancerCare Manitoba (CCMB)
Winnipeg, Manitoba, Canada
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Hamilton Regional Cancer Centre
Hamilton, Ontario, Canada
Kingston Regional Cancer Centre
Kingston, Ontario, Canada
London Regional Cancer Center
London, Ontario, Canada
Credit Valley Hospital
Mississauga, Ontario, Canada
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada
Group Health Centre
Saulte Ste. Marie, Ontario, Canada
Hotel Dieu Health Sciences HospitalNiagra
St. Catharines, Ontario, Canada
Toronto East General Hospital
Toronto, Ontario, Canada
Toronto-Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
St Joseph's Health Centre
Toronto, Ontario, Canada
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Hopital Du Sacre-Coeur
Montreal, Quebec, Canada
Hopital Laval
Ste-Foy, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Clinica Las Condes
Las Condes, , Chile
Charite Campus Virchow Klinikum
Berlin, , Germany
Universitatsklinikum Essen
Essen, , Germany
Tumor Biology Center
Freiburg im Breisgau, , Germany
Universitatskliniken des Saarlands Innere Medizin II
Hamburg, , Germany
Innere MedizinUniversitatsklinikum Heidelberg
Heidelberg, , Germany
Universitatskliniken des Saarlands
Homburg, , Germany
Medizinische Poliklinik der Universitaet Wurzburg
Würzburg, , Germany
Anticancer Hospital of Thessaloniki "THEAGENIO"
Thessaloniki, , Greece
District General Hospital of Thessaloniki "HIPPOKRATION"
Thessaloniki, , Greece
Rambam Medical Center
Haifa, , Israel
Rabin Medical Center (Belinson Campus)
Petach Tiqva, , Israel
Kaplan Medical Center
Rehovot, , Israel
Sourasky Medical Center (Ichikov)
Tel Aviv, , Israel
Chaim Sheba Medical Center
Tel Litwinsky, , Israel
Azienda Ospedaliera Universitaria Policlinico A.O.V.P. Oncologia Medica
Palermo, , Italy
Instituto Nacional De Cancerologia
Mexico City, , Mexico
Auckland Hospital
Auckland, , New Zealand
Christchurch HospitalClinical Oncology Hospital
Christchurch, , New Zealand
Great Poland Cancer Centre
Poznan, , Poland
Dolnoslaskie Centrum Onkologii
Wroclaw, , Poland
Oncology Institute Ion Chiricuta
Cluj-Napoca, , Romania
St. Spiridon University Hospital
Iași, , Romania
Clinical County Hospital Sibiu
Sibiu, , Romania
National University Hospital
Singapore, , Singapore
Singapore General Hospital
Singapore, , Singapore
National Cancer Centre
Singapore, , Singapore
ICRF Medical Oncology Unit
Oxford, Oxfordshire, United Kingdom
Velindre Hospital
Cardiff, Wales, United Kingdom
Russell's Hall HospitalDepartment of OncologyGeorgina Unit
Dudley, West Midlands, United Kingdom
Deanesly Centre
Wolverhampton, West Midlands, United Kingdom
The Princess Royal Hospital
Hull, , United Kingdom
St. Bartholomews Hospital
London, , United Kingdom
North Middlesex Hospital
London, , United Kingdom
Department of Medical Oncology
Manchester, , United Kingdom
Newcastle General Hospital
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23.
Shultz DB, Pai J, Chiu W, Ng K, Hellendag MG, Heestand G, Chang DT, Tu D, Moore MJ, Parulekar WR, Koong AC. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS One. 2016 Jan 25;11(1):e0147995. doi: 10.1371/journal.pone.0147995. eCollection 2016.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA.3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.